{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T22:33:47Z","timestamp":1789252427023,"version":"build-2803163510"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T00:00:00Z","timestamp":1735171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T00:00:00Z","timestamp":1735171200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2023JJ30841"],"award-info":[{"award-number":["2023JJ30841"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"DOI":"10.1007\/s10637-024-01494-4","type":"journal-article","created":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T11:48:15Z","timestamp":1735213695000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Clinical features, treatment, and outcomes of nivolumab induced psoriasis"],"prefix":"10.1007","author":[{"given":"Shaoli","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jichun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunjiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,26]]},"reference":[{"issue":"9","key":"1494_CR1","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.2217\/fon.15.52","volume":"11","author":"JR Brahmer","year":"2015","unstructured":"Brahmer JR, Hammers H, Lipson EJ (2015) Nivolumab: targeting PD-1 to bolster antitumor immunity. Future Oncol 11(9):1307\u20131326. https:\/\/doi.org\/10.2217\/fon.15.52","journal-title":"Future Oncol"},{"issue":"6","key":"1494_CR2","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1056\/NEJMoa2215530","volume":"389","author":"M Provencio","year":"2023","unstructured":"Provencio M, Nadal E, Gonz\u00e1lez-Larriba JL, Mart\u00ednez-Mart\u00ed A, Bernab\u00e9 R, Bosch-Barrera J et al (2023) Perioperative Nivolumab and Chemotherapy in Stage III Non-small-cell Lung Cancer. N Engl J Med 389(6):504\u2013513. https:\/\/doi.org\/10.1056\/NEJMoa2215530","journal-title":"N Engl J Med"},{"issue":"20","key":"1494_CR3","doi-asserted-by":"publisher","first-page":"6266","DOI":"10.1182\/bloodadvances.2023010334","volume":"7","author":"SM Ansell","year":"2023","unstructured":"Ansell SM, Br\u00f6ckelmann PJ, von Keudell G, Lee HJ, Santoro A, Zinzani PL, Cet (2023) Nivolumab for relapsed\/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study. Blood Adv 7(20):6266\u20136274. https:\/\/doi.org\/10.1182\/bloodadvances.2023010334","journal-title":"Blood Adv"},{"issue":"1","key":"1494_CR4","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1470-2045(21)00604-5","volume":"23","author":"T Yau","year":"2022","unstructured":"Yau T, Park JW, Finn RS, Cheng AL, Mathurin P, Edeline J et al (2022) Nivolumab versus Sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 23(1):77\u201390. https:\/\/doi.org\/10.1016\/S1470-2045(21)00604-5","journal-title":"Lancet Oncol"},{"issue":"1","key":"1494_CR5","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","volume":"6","author":"M Ramos-Casals","year":"2020","unstructured":"Ramos-Casals M, Brahmer JR, Callahan MK, Flores-Ch\u00e1vez A, Keegan N, Khamashta MA et al (2020) Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers 6(1):38. https:\/\/doi.org\/10.1038\/s41572-020-0160-6","journal-title":"Nat Rev Dis Primers"},{"issue":"10281","key":"1494_CR6","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","volume":"397","author":"CEM Griffiths","year":"2021","unstructured":"Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN, Psoriasis (2021) Lancet 397(10281):1301\u20131315. https:\/\/doi.org\/10.1016\/S0140-6736(20)32549-6","journal-title":"Lancet"},{"issue":"2","key":"1494_CR7","doi-asserted-by":"publisher","first-page":"e14830","DOI":"10.1111\/dth.14830","volume":"34","author":"P Cutroneo","year":"2021","unstructured":"Cutroneo P, Ingrasciotta Y, Isgr\u00f2 V, Rullo EV, Berretta M, Fiorica F et al (2021) Psoriasis and psoriasiform reactions secondary to immune checkpoint inhibitors. Dermatol Ther 34(2):e14830. https:\/\/doi.org\/10.1111\/dth.14830","journal-title":"Dermatol Ther"},{"key":"1494_CR8","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1146\/annurev-immunol-101320-125133","volume":"40","author":"NM Wilkinson","year":"2022","unstructured":"Wilkinson NM, Chen HC, Lechner MG, Su MA (2022) Sex differences in immunity. Annu Rev Immunol 40:75\u201394. https:\/\/doi.org\/10.1146\/annurev-immunol-101320-125133","journal-title":"Annu Rev Immunol"},{"issue":"11","key":"1494_CR9","doi-asserted-by":"publisher","first-page":"e1148","DOI":"10.1634\/theoncologist.2019-0094","volume":"24","author":"N Duma","year":"2019","unstructured":"Duma N, Abdel-Ghani A, Yadav S, Hoversten KP, Reed CT, Sitek AN et al (2019) Sex differences in tolerability to Anti-programmed Cell death protein 1 therapy in patients with metastatic melanoma and Non-small Cell Lung Cancer: are we all Equal? Oncologist 24(11):e1148\u2013e1155. https:\/\/doi.org\/10.1634\/theoncologist.2019-0094","journal-title":"Oncologist"},{"key":"1494_CR10","doi-asserted-by":"publisher","first-page":"701951","DOI":"10.3389\/fimmu.2021.701951","volume":"12","author":"L Zhou","year":"2021","unstructured":"Zhou L, Wei X (2021) Ocular Immune-related adverse events Associated with Immune checkpoint inhibitors in Lung Cancer. Front Immunol 12:701951. https:\/\/doi.org\/10.3389\/fimmu.2021.701951","journal-title":"Front Immunol"},{"issue":"7","key":"1494_CR11","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1089\/jwh.2021.0223","volume":"31","author":"A Buja","year":"2022","unstructured":"Buja A, Rugge M, Damiani G, Zorzi M, De Toni C, Vecchiato A et al (2022) Sex differences in cutaneous melanoma: incidence, Clinicopathological Profile, Survival, and costs. J Womens Health (Larchmt) 31(7):1012\u20131019. https:\/\/doi.org\/10.1089\/jwh.2021.0223","journal-title":"J Womens Health (Larchmt)"},{"issue":"3","key":"1494_CR12","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"1494_CR13","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.jaad.2022.02.030","volume":"87","author":"JT Said","year":"2022","unstructured":"Said JT, Elman SA, Perez-Chada LM, Mita C, Merola JF, LeBoeuf NR (2022) Treatment of immune checkpoint inhibitor-mediated psoriasis: a systematic review. J Am Acad Dermatol 87(2):399\u2013400. https:\/\/doi.org\/10.1016\/j.jaad.2022.02.030","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1494_CR14","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1016\/j.jaad.2020.08.137","volume":"84","author":"V Nikolaou","year":"2021","unstructured":"Nikolaou V, Sibaud V, Fattore D, Sollena P, Ortiz-Brugu\u00e9s A, Giacchero D et al (2021) Immune checkpoint-mediated psoriasis: a multicenter European study of 115 patients from the European Network for cutaneous adverse event to oncologic drugs (ENCADO) group. J Am Acad Dermatol 84(5):1310\u20131320. https:\/\/doi.org\/10.1016\/j.jaad.2020.08.137","journal-title":"J Am Acad Dermatol"},{"key":"1494_CR15","doi-asserted-by":"publisher","first-page":"m1590","DOI":"10.1136\/bmj.m1590","volume":"369","author":"R Parisi","year":"2020","unstructured":"Parisi R, Iskandar IYK, Kontopantelis E, Augustin M, Griffiths CEM, Ashcroft DM (2020) Global psoriasis Atlas. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ 369:m1590. https:\/\/doi.org\/10.1136\/bmj.m1590","journal-title":"BMJ"},{"issue":"8","key":"1494_CR16","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1002\/acr.23743","volume":"71","author":"L Eder","year":"2019","unstructured":"Eder L, Widdifield J, Rosen CF, Cook R, Lee KA, Alhusayen R et al (2019) Trends in the prevalence and incidence of Psoriasis and Psoriatic Arthritis in Ontario, Canada: a Population-based study. Arthritis Care Res (Hoboken) 71(8):1084\u20131091","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"10","key":"1494_CR17","doi-asserted-by":"publisher","first-page":"e003066","DOI":"10.1136\/jitc-2021-003066","volume":"9","author":"BR Halle","year":"2021","unstructured":"Halle BR, Betof Warner A, Zaman FY, Haydon A, Bhave P, Dewan AK et al (2021) Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy. J Immunother Cancer 9(10):e003066. https:\/\/doi.org\/10.1136\/jitc-2021-003066","journal-title":"J Immunother Cancer"},{"issue":"19","key":"1494_CR18","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","volume":"323","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Read C, Pathophysiology (2020) Clinical presentation, and treatment of psoriasis: a review. JAMA 323(19):1945\u20131960. https:\/\/doi.org\/10.1001\/jama.2020.4006","journal-title":"JAMA"},{"issue":"1","key":"1494_CR19","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1080\/15569527.2022.2034842","volume":"41","author":"M Bhardwaj","year":"2022","unstructured":"Bhardwaj M, Chiu MN, Pilkhwal Sah S (2022) Adverse cutaneous toxicities by PD-1\/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance. Cutan Ocul Toxicol 41(1):73\u201390. https:\/\/doi.org\/10.1080\/15569527.2022.2034842","journal-title":"Cutan Ocul Toxicol"},{"issue":"1","key":"1494_CR20","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00281-015-0539-8","volume":"38","author":"SK Mahil","year":"2016","unstructured":"Mahil SK, Capon F, Barker JN (2016) Update on psoriasis immunopathogenesis and targeted immunotherapy. Semin Immunopathol 38(1):11\u201327. https:\/\/doi.org\/10.1007\/s00281-015-0539-8","journal-title":"Semin Immunopathol"},{"issue":"1","key":"1494_CR21","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1038\/s42003-020-01308-2","volume":"3","author":"R Tanaka","year":"2020","unstructured":"Tanaka R, Ichimura Y, Kubota N, Saito A, Nakamura Y, Ishitsuka Y et al (2020) Activation of CD8 T cells accelerates anti-PD-1 antibody-induced psoriasis-like dermatitis through IL-6. Commun Biol 3(1):571. https:\/\/doi.org\/10.1038\/s42003-020-01308-2","journal-title":"Commun Biol"},{"issue":"10","key":"1494_CR22","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1111\/j.1346-8138.2012.01544.x","volume":"39","author":"T Kamiyama","year":"2012","unstructured":"Kamiyama T, Watanabe H, Iijima M, Miyazaki A, Iwamoto S (2012) Coexpression of CCR6 and CD146 (MCAM) is a marker of effector memory T-helper 17 cells. J Dermatol 39(10):838\u2013842. https:\/\/doi.org\/10.1111\/j.1346-8138.2012.01544.x","journal-title":"J Dermatol"},{"issue":"2","key":"1494_CR23","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1159\/000491572","volume":"10","author":"M De Bock","year":"2018","unstructured":"De Bock M, Hulstaert E, Kruse V, Brochez L (2018) Psoriasis Vulgaris Exacerbation during treatment with a PD-1 checkpoint inhibitor: Case Report and Literature Review. Case Rep Dermatol 10(2):190\u2013197. https:\/\/doi.org\/10.1159\/000491572","journal-title":"Case Rep Dermatol"},{"issue":"3","key":"1494_CR24","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1111\/jdv.17855","volume":"36","author":"Z Apalla","year":"2022","unstructured":"Apalla Z, Nikolaou V, Fattore D, Fabbrocini G, Freites-Martinez A, Sollena P et al (2022) European recommendations for management of immune checkpoint inhibitors-derived dermatologic adverse events. The EADV task force \u2018Dermatology for cancer patients\u2019 position statement. J Eur Acad Dermatol Venereol 36(3):332\u2013350. https:\/\/doi.org\/10.1111\/jdv.17855","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1494_CR25","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jaad.2021.07.040","volume":"86","author":"L Stein Gold","year":"2022","unstructured":"Stein Gold L, Papp K, Pariser D, Green L, Bhatia N, Sofen H et al (2022) Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 86(1):77\u201385. https:\/\/doi.org\/10.1016\/j.jaad.2021.07.040","journal-title":"J Am Acad Dermatol"},{"key":"1494_CR26","doi-asserted-by":"publisher","unstructured":"Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J et al (2017) Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 28(suppl_4):iv119-iv142. https:\/\/doi.org\/10.1093\/annonc\/mdx225. Erratum in: Ann Oncol. 2018;29(Suppl 4):iv264-iv266. doi: 10.1093\/annonc\/mdy162","DOI":"10.1093\/annonc\/mdx225"},{"issue":"6","key":"1494_CR27","doi-asserted-by":"publisher","first-page":"e829","DOI":"10.1016\/j.cllc.2021.04.002","volume":"22","author":"H Furuta","year":"2021","unstructured":"Furuta H, Kato S, Masago K, Hida T (2021) Palmoplantar Pustulosis caused by Immune-Checkpoint inhibitors. Clin Lung Cancer 22(6):e829\u2013e832. https:\/\/doi.org\/10.1016\/j.cllc.2021.04.002","journal-title":"Clin Lung Cancer"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-024-01494-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-024-01494-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-024-01494-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T12:02:55Z","timestamp":1735214575000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-024-01494-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,26]]},"references-count":27,"alternative-id":["1494"],"URL":"https:\/\/doi.org\/10.1007\/s10637-024-01494-4","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,26]]},"assertion":[{"value":"7 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study did not require an ethical board approval because the study was a retrospective study and did not involve sensitive personal information.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}